Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes

December 4, 2024

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.

Target Audience

This educational program is intended for urologists, urologic oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select therapy for bladder cancer—including non-muscle-invasive, muscle-invasive, locally advanced, and metastatic disease—taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
  • Plan individualized treatment approaches for patients with nonmetastatic or metastatic bladder cancer that progresses on first-line therapy, based on optimal guideline recommended therapy sequence and assessment of patient and tumor factors that could affect efficacy
  • Monitor patients with bladder cancer on immunotherapy, chemotherapy, or gene therapy for treatment-related adverse events, and employ optimal medical and pharmacologic management strategies
  • Counsel individual patients with non-metastatic or metastatic bladder cancer on the potential for enrollment on ongoing investigational clinical trial based on eligibility, due to failed therapeutic response, unique mechanism of action

You may also be interested in

NCCN Guidelines® Insights - Bladder Cancer, Version 3.2024
These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Additional information
Supporters: 

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. and Astellas.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/04/2024
Course expires: 
01/12/2025
Event starts: 
12/04/2024 - 8:00am EST
Event ends: 
12/04/2024 - 9:00am EST
Cost:
$0.00
Add to calendar: 

Fed Ghali, MD
Assistant Professor
Division of Urologic Oncology
Department of Urology
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Tian Zhang, MD, MHS
Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
Associate Director of Clinical Research
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Fed Ghali, MD

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Tian Zhang, MD, MS
ALX Oncology Inc.: Grant/Research Support
Amgen Inc.: Consultant/Advisor
Aptitude Health: Consultant/Advisor
Aravive, Inc.: Consultant/Advisor
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consultant/Advisor; Grant/Research Support
AVEO Pharmaceuticals, Inc.: Consultant/Advisor
Bayer HealthCare: Consultant/Advisor; Grant/Research Support
Bristol Myers Squibb: Consultant/Advisor
Caris Life Sciences: Consultant/Advisor
Dendreon Pharmaceuticals LLC: Consultant/Advisor
Eisai Inc.: Consultant/Advisor
Eli Lilly and Company: Consultant/Advisor; Grant/Research Support
EMD Serono Inc.: Consultant/Advisor
Exelixis Inc.: Consultant/Advisor; Grant/Research Support
Gilead Sciences, Inc.: Consultant/Advisor
Janssen Pharmaceutica Products, LP: Consultant/Advisor; Grant/Research Support
Janux Therapeutics: Grant/Research Support
Merck & Co., Inc.: Consultant/Advisor; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consultant/Advisor; Grant/Research Support
OncoC4, Inc.: Grant/Research Support 
Pfizer Inc.: Consultant/Advisor; Grant/Research Support 
Pharmacyclics LLC: Consultant/Advisor
QED Therapeutics, Inc.: Consultant/Advisor
sanofi-aventis U.S.: Consultant/Advisor
SeaGen: Consultant/Advisor
Tempus AI, Inc.: Grant/Research Support 
Vaniam Group LLC: Consultant/Advisor
Xencor: Consultant/Advisor

NCCN/CCO Staff Disclosures

None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-113-L01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing